SCHEMBL6469732

SCHEMBL6469732

COC(=O)c1c(-c2ccc(C#N)cc2)c(C)n(Cc2ccc(C(=O)O)cc2)c1C

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 13/20 0.82
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
KDM4E B2RXH2 2/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
NR4A1 P22736 1/20 0.43
APEX1 P27695 1/20 0.43
APOBEC3A P31941 1/20 0.43
RECQL P46063 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HIF1A Q16665 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6465312 0.93 AR (0.89) ARCYP11B1CYP11B2KDM4EMEN1
SCHEMBL6469313 0.91 AR (0.77) ARCYP11B1CYP11B2KDM4EMAPT
SCHEMBL6468911 0.90 AR (1.00) ARALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL6469628 0.90 AR (0.76) ARCYP11B1CYP11B2KDM4EPOLB
SCHEMBL6465292 0.89 AR (0.82) ARCYP11B1CYP11B2KDM4EALDH1A1
SCHEMBL6469536 0.89 AR (0.74) ARCYP11B1CYP11B2KDM4EMAPT
SCHEMBL6466721 0.88 AR (0.80) ARCYP11B1CYP11B2KDM4EMEN1
SCHEMBL6468792 0.88 AR (0.80) ARCYP11B1CYP11B2KDM4EMEN1
SCHEMBL6468830 0.86 AR (0.80) ARCYP11B1CYP11B2KDM4EMEN1
SCHEMBL6468062 0.84 AR (1.00) ARKDM4EMEN1USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050101657-A1 Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative TAKEDA CHEMICAL INDUSTRIES LTD. (JP) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101657-A1 Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative SHBG, PRLHR, FSHR AR 6/4885CYP11B1 145/4885CYP11B2 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.